Japanese drugmaker Daiichi Sankyo (TYO: 4568), Mitsubishi UFJ Capital and Tokyo Institute of Technology today announced that they will commence open innovation research with the aim of creating insulin producing cells from iPS cells for use in regenerative medicine and cell therapy.
The Kume and Shiraki Lab at the School of Life Science and Technology, Tokyo Tech, has developed a technique to produce pancreatic β cells (insulin secreting cells in the pancreas) derived from human iPS cells at a high rate. It has been found that this technique enables creation of iPS cell-derived insulin producing cells similar to the body’s own pancreatic β cells in combination with Daiichi Sankyo technology.
The research will improve the performance and manufacturing process for such iPS cell-derived insulin producing cells, aiming at practical application as an innovative therapy for severe type I diabetes, for which blood glucose management is difficult with conventional insulin therapy, and in which high unmet medical needs exist.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze